Is BCRX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,006 people get BCRX articles and Market Currents by email alert.

Get email alerts on BCRX »

HEADLINES:

BioCryst to Present at Two Upcoming Investor Conferences

Business Wire (May 9, 2013)
BioCryst Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 7
BioCryst Provides Corporate Update and Reports First Quarter 2013 Financial Results

Business Wire (May 7, 2013)
BioCryst Heats Up: H7N9 Virus Hits Taiwan, Fatalities Up Nearly 300%
Brian L. Wilson • Thu, Apr 25 • 2 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Thu, Apr 25 • 1 Comment
BioCryst to Announce First Quarter 2013 Financial Results May 7

Business Wire (Apr 23, 2013)
3 Microcap Biopharma Plays For The H7N9 Influenza Outbreak
Healthcare Specialist • Tue, Apr 16 • 18 Comments
BioCryst Pharmaceuticals Completes Peramivir Type C Meeting

Business Wire (Apr 16, 2013)
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Wed, Apr 10
BioCryst's Influenza Drug Brought Back From The Dead
Brian L. Wilson • Mon, Apr 8 • 5 Comments
Flu Stocks For Investors To Consider
Stock Investor • Mon, Apr 8 • 6 Comments
Biotechs Ramping Up On China's Avian Flu Outbreak
David Zanoni • Mon, Apr 8 • 12 Comments
BioCryst Pharmaceuticals Provides Update Regarding Peramivir

Business Wire (Apr 1, 2013)
BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4161 for the Treatment of Hereditary Angioedema

Business Wire (Mar 25, 2013)
3 Biotech Stocks Ready To Rally
BuySellShort • Wed, Mar 6 • 8 Comments
Following Crashing Biotechs - 5 Bargains To Consider
Craig Keolanui • Tue, Feb 26 • 5 Comments
BioCryst Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Feb 19
BioCryst Reports Fourth Quarter and Full Year 2012 Financial Results

Business Wire (Feb 19, 2013)
BioCryst to Announce Fourth Quarter & 2012 Financial Results on February 19, 2013

Business Wire (Feb 5, 2013)
BioCryst Makes A Small Recovery Following Last Year's Bad News
Brian L. Wilson • Wed, Jan 16

To learn more about Seeking Alpha Pro, click here.

BioCryst Heats Up: H7N9 Virus Hits Taiwan, Fatalities Up Nearly 300%
Brian L. Wilson • Thu, Apr 25 • 2 Comments
BioCryst's Influenza Drug Brought Back From The Dead
Brian L. Wilson • Mon, Apr 8 • 5 Comments
BioCryst Makes A Small Recovery Following Last Year's Bad News
Brian L. Wilson • Wed, Jan 16
BioCryst Investors Breathe Sight Of Relief, But What's Next?
EP Vantage • Mon, Dec 3, 2012 • 1 Comment
Shares Of BioCryst Pop On Merger Termination, But Gains Are Temporary
PropThink • Fri, Nov 30, 2012 • 2 Comments
BioCryst Erases Year's Gains On A Failed HCV Preclinical Program
Brian L. Wilson • Tue, Nov 6, 2012 • 3 Comments
With Some Cost Cutting, BioCryst Pharmaceuticals Would Look Great
Roy Manning III • Mon, Apr 16, 2012 • 6 Comments
Investors Digest BioCryst's New Data
M. E. Garza • Wed, Nov 9, 2011 • 1 Comment
BioCryst Pharmaceuticals Gears Up for a New Round of Swine Flu
Michael J. Ray • Sun, Jun 12, 2011 • 3 Comments
BioCryst Drug Receives Recommendation for Pediatric Approval in Japan
Michael Murphy • Mon, Sep 27, 2010
BioCryst: Peramivir Approval Opens Japanese Market
Michael Murphy • Wed, Jan 13, 2010 • 5 Comments
BioCryst: Israel Orders 150 Doses of H1N1 Antiviral Peramivir
Michael Murphy • Mon, Dec 21, 2009 • 4 Comments
BioCryst: H1N1 Antiviral Partner Gets Fast Tracked for Japanese Review
Michael Murphy • Wed, Dec 9, 2009 • 14 Comments
BioCryst's Korean Partner Receives Emergency Use Authorization
Michael Murphy • Wed, Dec 9, 2009 • 26 Comments
BioCryst Management Needs to Earn Investors' Trust
Michael Shulman • Tue, Feb 5, 2008 • 1 Comment
BioCryst Receives Fast-Track Status for Peramivir, But Does It Justify The Stock's Appreciation? (BCRX)
BioBlogger • Wed, Jan 18, 2006 • 2 Comments
BioCryst and Avian Flu: Underappreciated Call Option or Just Overhyped? (BCRX)
BioBlogger • Wed, Oct 12, 2005 • 5 Comments

Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Thu, Apr 25 • 1 Comment
3 Microcap Biopharma Plays For The H7N9 Influenza Outbreak
Healthcare Specialist • Tue, Apr 16 • 18 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Wed, Apr 10
Flu Stocks For Investors To Consider
Stock Investor • Mon, Apr 8 • 6 Comments
Biotechs Ramping Up On China's Avian Flu Outbreak
David Zanoni • Mon, Apr 8 • 12 Comments
3 Biotech Stocks Ready To Rally
BuySellShort • Wed, Mar 6 • 8 Comments
Following Crashing Biotechs - 5 Bargains To Consider
Craig Keolanui • Tue, Feb 26 • 5 Comments
Change In Global Weather Patterns, Australia Heat Wave, Flu Virus
James Roemer • Mon, Jan 14 • 5 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Mon, Jan 14
Speculative Flu Vaccine Stocks To Consider: Novavax, iBio, BioCryst, And Inovio
BuySellShort • Fri, Jan 11 • 14 Comments
The Best And Worst Of Earnings Season
Bespoke Investment Group • Fri, Nov 16, 2012
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Fri, Nov 9, 2012
2 Biotech Stocks Experiencing Significant Sell-Offs Investors Should Avoid
Matt Schilling • Thu, Nov 8, 2012 • 2 Comments
2 Biotech Companies With Positive Results That May Be Headed In Opposite Directions
Matt Schilling • Thu, Nov 8, 2012
Biotech Weekend Recap: Earnings Reports And Disappointments
Brian L. Wilson • Mon, Nov 5, 2012 • 1 Comment
What Moves Biotech Stocks? Ed Arce Has Answers
Life Sciences Report • Thu, Oct 18, 2012
Tracking Recent Buy Calls And Investments By The Maxim Group
Scott Matusow • Fri, Sep 28, 2012 • 31 Comments
7 Innovative Biotechs That Could Soar By Year-End: George Zavoico
Life Sciences Report • Thu, Sep 13, 2012 • 1 Comment
5 Pharmaceutical Companies With Phase III Clinical Study Catalysts This Year - Part IV
Markus Aarnio • Mon, Aug 20, 2012 • 6 Comments
6 Rallying Biotech Stocks With Strong Receivable Trends
Kapitall • Sun, Jul 22, 2012 • 1 Comment

BioCryst Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 7
BioCryst Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Feb 19
BioCryst Pharmaceuticals Management Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Nov 8, 2012
BioCryst Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Aug 2, 2012
BioCryst Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript
Wed, Apr 28, 2010
BioCryst Pharmaceuticals, Inc. Q4 2009 Earnings Call Transcript
Thu, Feb 4, 2010
BioCryst Pharmaceuticals, Inc. Q4 2007 Earnings Call Transcript
Mon, Mar 24, 2008

BioCryst to Present at Two Upcoming Investor Conferences

Business Wire (May 9, 2013)
BioCryst Provides Corporate Update and Reports First Quarter 2013 Financial Results

Business Wire (May 7, 2013)
BioCryst to Announce First Quarter 2013 Financial Results May 7

Business Wire (Apr 23, 2013)
BioCryst Pharmaceuticals Completes Peramivir Type C Meeting

Business Wire (Apr 16, 2013)
Market Snapshot: U.S. stocks rise on ‘buy-the-dip’ mentality

at MarketWatch.com (Apr 8, 2013)
Indications: Stock futures rebound with Alcoa ahead

at MarketWatch.com (Apr 8, 2013)
BioCryst Pharmaceuticals Provides Update Regarding Peramivir

Business Wire (Apr 1, 2013)
BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4161 for the Treatment of Hereditary Angioedema

Business Wire (Mar 25, 2013)
BioCryst Reports Fourth Quarter and Full Year 2012 Financial Results

Business Wire (Feb 19, 2013)
BioCryst to Announce Fourth Quarter & 2012 Financial Results on February 19, 2013

Business Wire (Feb 5, 2013)
BioCryst to Present at J.P. Morgan Healthcare Conference

Business Wire (Jan 2, 2013)
BioCryst Pharmaceuticals Announces Focused Corporate Strategy and Restructuring

Business Wire (Dec 7, 2012)
BioCryst Pharmaceuticals and Presidio Pharmaceuticals Mutually Terminate Merger Transaction

Business Wire (Nov 30, 2012)
BioCryst Broad-Spectrum Antiviral BCX4430 Highly Effective against Yellow Fever in a Preclinical Disease Model

Business Wire (Nov 12, 2012)
Movers & Shakers: Thursday’s biggest movers; Apple at 5-month low

at MarketWatch.com (Nov 8, 2012)
BioCryst Provides Corporate Update and Reports Third Quarter 2012 Financial Results

Business Wire (Nov 8, 2012)
BioCryst Announces Outcome from the Peramivir Phase 3 Interim Analysis

Business Wire (Nov 7, 2012)
BioCryst to Report Third Quarter 2012 Financial Results on November 8, 2012

Business Wire (Nov 1, 2012)
BioCryst Provides Update Regarding BCX5191 Development Plan Following Discussion With FDA

Business Wire (Oct 30, 2012)
BioCryst Pharmaceuticals and Presidio Pharmaceuticals to Merge

Business Wire (Oct 18, 2012)

BCRX vs. ETF Alternatives

Company Description

BioCryst Pharmaceuticals, Inc. is a biotechnology company that designs, optimizes and develops novel drugs that block key enzymes involved in cancer, viral infections and autoimmune diseases. BioCryst integrates the disciplines of biology, crystallography, medicinal chemistry and computer... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 7, 6:08 AM BioCryst Pharm (BCRX): Q1 EPS of -$0.09 beats by $0.03. Revenue of $3.6M beats by $2.29M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, May 7, 12:05 AM Notable earnings before Tuesday’s open: ACM, AFAM, AKRX, ALLT, ARCC, ARIA, BCRX, CHTR, CMLP, CNK, CQB, CRZO, CVLT, DFT, DISCA, DTV, DWRE, EMR, ENDP, FE, FOSL, HCN, HFC, HPT, HSIC, KWK, LPX, NRG, NRGY, NVAX, OAK, OMX, PQ, PRGO, RIGL, SHOO, TA, TAP, TDG, TGH, TICC, TRGT, TW, WRES, XEC 2 Comments [Earnings]
Monday, May 6, 5:30 PM Notable earnings before Tuesday's open: ACM, AFAM, AKRX, ALLT, ARCC, ARIA, BCRX, CHTR, CMLP, CNK, CQB, CRZO, CVLT, DFT, DISCA, DTV, DWRE, EMR, ENDP, FE, FOSL, HCN, HFC, HPT, HSIC, KWK, LPX, NRG, NRGY, NVAX, OAK, OMX, PQ, PRGO, RIGL, SHOO, TA, TAP, TDG, TGH, TICC, TRGT, TW, WRES, XEC Comment! [Earnings]
Wednesday, April 24, 11:37 AM BioCryst Pharmaceuticals (BCRX +8.3%) pops again today on bird flu concerns out of China, this time that catalyst comes from comments made out of the World Health Organization today, saying that the H7N9 is "one of the most lethal" strains of the bird flu virus compared to one that has killed about 371 since 2003. Since being discovered in March, the H7N9 has killed 22 and inflected just over 100 people. Comment! [Healthcare, Global & FX, On the Move]
Tuesday, April 16, 10:44 AM Shares in BioCryst Pharmaceuticals (BCRX +3.8%) are higher today after the company announces it's completed its Type C meeting on peramivir with the FDA and confirmed that its proposed New Drug Application content supports a reviewable submission for the indication of acute uncomplicated influenza. The company says it's now in the process of requesting a pre-NDA meeting to reach agreement on a complete NDA submission and to address review issues identified in the minutes. Comment! [Healthcare, On the Move]
Tuesday, April 16, 9:10 AM Premarket gainers: NWBO +9%. GFI +7%. BCRX +7%. HK +7%. AU +7%. NG +6%. AUQ +6%. SAND +6%. GOLD +5%. KGC +5%.
Losers: LDK -16%. SRPT -11%. 1 Comment [On the Move]
Monday, April 15, 10:28 AM BioCryst (BCRX +5%) moves up again today, adding to last week's gains as the number of bird flu cases in China continues to increase. Recent reports now have the death toll at 14, with 61 confirmed cases. The stock has climbed nearly 21% in the past week, after China moved to expedite approval of it's anti-flu drug, Permavir, after six new cases of the H7N9 virus were diagnosed. Comment! [Healthcare, Global & FX, On the Move]
Monday, April 15, 9:15 AM Premarket gainers: S +16%. SVA +13%. BCRX +10%. LIFE +8%. NFP +7%. MGT +7%. TMO +6%. THRX +5%. NVAX +5%.
Losers: AAU -15%. MTL -10%. AUQ -11%. HMY -9%. NGD -8%. CEF -8%. SLW -8%. SAND -9%. KGC -7%. AUY -7%. GOLD -7%. MUX -7%. DSCO -7%. IAG -6%. SVM -6%. GG -6%. PAAS -6%. EGO -6%. AU -5%. CDE -5%. Comment! [On the Move]
Monday, April 15, 8:39 AM Biotechs rise in early trading as the death toll from the new avian flu strain jumps to 13. Sinovac (SVA) is preparing immunizations and can manufacture 30-40M doses annually, according to Bloomberg. Meanwhile, investors continue to bet BioCryst's (BCRX) peramavir could have a role to play. Premarket moves: SVA +9.6%, BCRX +7.4%, NVAX +5%. Comment! [On the Move, Healthcare]
Tuesday, April 9, 8:03 AM BioCryst Pharma (BCRX) gets an upgrade to Buy from Hold at MLV whose analyst Ed Arce called the stock "a complete turnaround story" yesterday. The stock has rallied hard on speculation the company's drug peramavir may play a role in helping China combat a new strain of avian flu. Some however, believe the hype is overdone. Shares +4.7% premarket. Comment!
Monday, April 8, 3:30 PM JMP Securities analyst Lisa Bayko says the rally in BioCryst Pharma (BCRX +10%) on the China/Permivir news is overdone. She points out that BCRX has no patent in China for Peramivir, hasn't been involved in any drug approval, and "won't receive economics from use there." BCRX appears to agree. saying it doesn't even have a partner or any in-country operations in the region. TheStreet.com's Adam Fuerstein quips that the drug developer "isn't likely to see a dime" from drug sales there. Comment! [Healthcare, On the Move]
Monday, April 8, 9:10 AM Premarket gainers: LUFK +38%. BSDM +34%. BCRX +18%. UNXL +15%. GOL +10%. TSL +7%.
Losers: OMPI -6%. DCTH -5%. Comment! [On the Move]
Monday, April 8, 8:28 AM BioCryst Pharmaceuticals (BCRX) looks to post outsized gains for the second straight session as China expedites approval for its Peramivir drug amid worries about a new strain of avian flu. The shares rose sharply on Friday as the death toll from the new virus rose to six. Shares +21% premarket. Comment! [Healthcare, On the Move]
Friday, April 5, 11:09 AM BioCryst Pharmaceuticals (BCRX +17.4%) pops on news that six deaths in China have been linked to a new strain of avian flu. BCRX is developing peramivir, which has been shown in preclinical studies to help treat highly virulent strains of influenza - including the bird flu strain known as the H5N1 virus. Other drug stocks moving higher on the news: Pure Bioscience (PURE +15.6%), Hemispherx BioPharma (HEB +13.3%), Sinovac Biotech (SVA +7.8%), and Novavax (NVAX +1.1%). Comment! [Healthcare, On the Move]
Monday, April 1, 9:11 AM Premarket gainers: KWK +33%. BCRX +30%. SNFCA +23%. TSLA +16%. AM +12%. VRNG +10%. PAL +6%. Comment! [On the Move]
Monday, April 1, 8:29 AM BioCryst Pharmaceuticals (BCRX) receives a letter from FDA which it says "outlines a pathway by which an NDA [could be filed] seeking regulatory approval of intravenous permavir." Last November, shares were nearly cut in half after permavir disappointed in clinical trials. Shares +15% premarket. Comment! [Healthcare]

Ryan Mallory
Fuinhaz Setups for April 8 2013 | $AMRN $BCRX $FSLR $GLUU $PERI $RIGL $SRPT $SVA $ZNGA | http://bit.ly/10MTLwT
Apr 8, 9:11 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

denewa
downgrade from 1 to 3 at zacks $BCRX
Feb 6, 7:06 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

denewa
zacks rank $BCRX : 1- strong buy
Jan 18, 3:25 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ecneralc
My sense of $BCRX is that it is a ne'er-do-well.
Jan 15, 1:47 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

B___________
$BCRX about to POP above $2 on speculation.
Jan 12, 11:08 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://stks.co/jE5o Stocks for Nov 1st: $CRUS, $ZUMZ, $ELLI, $BCRX, $OTEX http://stks.co/fEE2
10/31/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Clark
BUY: PCLN, TXT, BCRX, JDSU. VIX. SHORT: SCHN, XOMA, CORT, AOBI. Momentum still down in markets. http://seekingalpha.com/p/j7sh
7/26/12
Reply (5)

• !Report Abuse
View all 5 replies
Michael Clark: He's a clown. Actually the markets move up and down like a breathing process. The talking head say this caused that and that caused this.
7/26/12
• !Report Abuse
Michael Clark: In truth, the market breathed out; and will soon again breathe in. European system isn't fixed. They've said their in charge before.
7/26/12
• !Report Abuse
Add a reply...

140 characters

Roy Manning III
BCRX has sold off alot. I would consider it a buy now. News on a Gout drug partner or their Hep C. patent could push the stock higher.
5/7/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/KW1sxj Earnings premarket $FLWS $ARG $ANR $ANSS $BCRX $CAH $CI $CNP, $EXXI $GM $LVLT $OWW $GOLD $VIAB $SNTA $HSH
5/3/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LT
took a small opening long position in SQQQ, BCRX, PWER
2/28/12
Reply (1)

• !Report Abuse
View all 1 replies
jdub2788: SQQQ - welcome to the dark side.
2/28/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Michael Clark
BUY: PCLN, TXT, BCRX, JDSU. VIX. SHORT: SCHN, XOMA, CORT, AOBI. Momentum still down in markets. http://seekingalpha.com/p/j7sh
7/26/12
Reply (5)

• !Report Abuse
View all 5 replies
Michael Clark: He's a clown. Actually the markets move up and down like a breathing process. The talking head say this caused that and that caused this.
7/26/12
• !Report Abuse
Michael Clark: In truth, the market breathed out; and will soon again breathe in. European system isn't fixed. They've said their in charge before.
7/26/12
• !Report Abuse
Add a reply...

140 characters

LT
Bought VRTX this morning, nice gain so far, looking at BCRX next for hep C play.
2/27/12
Reply (1)

• !Report Abuse
View all 1 replies
mitrado: Still holding $VRTX!? I've sold at 37.5$ ... watched it fly up to 41$ ... and I've just got back in at 36.45$.
4/13/12
• !Report Abuse
Add a reply...

140 characters

LT
took a small opening long position in SQQQ, BCRX, PWER
2/28/12
Reply (1)

• !Report Abuse
View all 1 replies
jdub2788: SQQQ - welcome to the dark side.
2/28/12
• !Report Abuse
Add a reply...

140 characters

BCRX BioCryst Pharmaceuticals, Inc.

BCRX

BioCryst Pharmaceuticals, Inc.